Key Insights

Highlights

Treatment Research

3 treatments under study, led by 68gagadotastr17126

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Early Phase 1 (1)
Phase 1 (1)

Trial Status

Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07608848Early Phase 1Recruiting

First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer

NCT04849247Phase 1Unknown

68Ga-DOTA-FAPI and 177Lu-DOTA-FAPI Theranostic Pair in Patients With Various Types of Cancer (Locally Advanced or Metastatic Cancer)

Showing all 2 trials

Research Network

Common Treatments

  • 68gagadotastr171261
  • 177luludotastr171261
  • 68gadotafapi 177ludotafapi1

Active Sponsors

  • Integrated Haematology and Oncology Network1
  • The First Affiliated Hospital of Xiamen University1

Top Investigators

Related Conditions

  • 177ludotafapi1
  • Theranostic Radiopharmaceuticals1
  • Active Cancer1
  • Cancer1
  • Metastatic Breast Cancer1

Activity Timeline